Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

The antitubercular activity of various nitro(triazole/imidazole)-based compounds.

Papadopoulou MV, Bloomer WD, Rosenzweig HS.

Bioorg Med Chem. 2017 Nov 1;25(21):6039-6048. doi: 10.1016/j.bmc.2017.09.037. Epub 2017 Sep 28.

PMID:
28993106
2.

The antitrypanosomal and antitubercular activity of some nitro(triazole/imidazole)-based aromatic amines.

Papadopoulou MV, Bloomer WD, Rosenzweig HS, Kaiser M.

Eur J Med Chem. 2017 Sep 29;138:1106-1113. doi: 10.1016/j.ejmech.2017.07.060. Epub 2017 Jul 25.

PMID:
28763645
3.

Nitrotriazole-Based Compounds as Antichagasic Agents in a Long-Treatment In Vivo Assay.

Papadopoulou MV, Bloomer WD, Rosenzweig HS, Mazzeti AL, Gonçalves KR, Mendes PF, Bahia MT.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02717-16. doi: 10.1128/AAC.02717-16. Print 2017 May.

4.

Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity.

Papadopoulou MV, Bloomer WD, Rosenzweig HS, Wilkinson SR, Szular J, Kaiser M.

Eur J Med Chem. 2016 Nov 10;123:895-904. doi: 10.1016/j.ejmech.2016.08.002. Epub 2016 Aug 9.

5.

Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds.

Papadopoulou MV, Bloomer WD, Rosenzweig HS, Wilkinson SR, Szular J, Kaiser M.

Eur J Med Chem. 2016 Jul 19;117:179-86. doi: 10.1016/j.ejmech.2016.04.010. Epub 2016 Apr 8.

6.

3-Nitrotriazole-based piperazides as potent antitrypanosomal agents.

Papadopoulou MV, Bloomer WD, Rosenzweig HS, O'Shea IP, Wilkinson SR, Kaiser M.

Eur J Med Chem. 2015 Oct 20;103:325-34. doi: 10.1016/j.ejmech.2015.08.042. Epub 2015 Sep 4.

PMID:
26363868
7.

Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.

Papadopoulou MV, Bloomer WD, Rosenzweig HS, O'Shea IP, Wilkinson SR, Kaiser M, Chatelain E, Ioset JR.

Bioorg Med Chem. 2015 Oct 1;23(19):6467-76. doi: 10.1016/j.bmc.2015.08.014. Epub 2015 Aug 24.

PMID:
26344593
8.

Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents.

Papadopoulou MV, Bloomer WD, Lepesheva GI, Rosenzweig HS, Kaiser M, Aguilera-Venegas B, Wilkinson SR, Chatelain E, Ioset JR.

J Med Chem. 2015 Feb 12;58(3):1307-19. doi: 10.1021/jm5015742. Epub 2015 Jan 23.

9.

Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.

Papadopoulou MV, Bloomer WD, Rosenzweig HS, Wilkinson SR, Kaiser M.

Eur J Med Chem. 2014 Nov 24;87:79-88. doi: 10.1016/j.ejmech.2014.09.045. Epub 2014 Sep 16.

PMID:
25240098
10.

Nitrotriazole- and imidazole-based amides and sulfonamides as antitubercular agents.

Papadopoulou MV, Bloomer WD, Rosenzweig HS, Arena A, Arrieta F, Rebolledo JC, Smith DK.

Antimicrob Agents Chemother. 2014 Nov;58(11):6828-36. doi: 10.1128/AAC.03644-14. Epub 2014 Sep 2.

11.

Efficacy of preventive interventions for iodinated contrast-induced acute kidney injury evaluated by intrarenal oxygenation as an early marker.

Li LP, Thacker J, Lu J, Franklin T, Zhou Y, Papadopoulou MV, Solomon R, Prasad PV.

Invest Radiol. 2014 Oct;49(10):647-52. doi: 10.1097/RLI.0000000000000065.

12.

Evaluation of intrarenal oxygenation in iodinated contrast-induced acute kidney injury-susceptible rats by blood oxygen level-dependent magnetic resonance imaging.

Li LP, Lu J, Zhou Y, Papadopoulou MV, Franklin T, Bokhary U, Solomon R, Sen A, Prasad PV.

Invest Radiol. 2014 Jun;49(6):403-10. doi: 10.1097/RLI.0000000000000031.

13.

Novel 3-nitro-1H-1,2,4-triazole-based compounds as potential anti-Chagasic drugs: in vivo studies.

Papadopoulou MV, Bloomer WD, Rosenzweig HS, Ashworth R, Wilkinson SR, Kaiser M, Andriani G, Rodriguez A.

Future Med Chem. 2013 Oct;5(15):1763-76. doi: 10.4155/fmc.13.108.

14.

Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents.

Papadopoulou MV, Bloomer WD, Rosenzweig HS, Kaiser M, Chatelain E, Ioset JR.

Bioorg Med Chem. 2013 Nov 1;21(21):6600-7. doi: 10.1016/j.bmc.2013.08.022. Epub 2013 Aug 20.

15.

Evaluating the developmental toxicity of trypanocidal nitroaromatic compounds on zebrafish.

Buchanan-Kilbey G, Djumpah J, Papadopoulou MV, Bloomer W, Hu L, Wilkinson SR, Ashworth R.

Acta Trop. 2013 Dec;128(3):701-5. doi: 10.1016/j.actatropica.2013.07.022. Epub 2013 Aug 2.

PMID:
23916507
16.

Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.

Papadopoulou MV, Bloomer WD, Rosenzweig HS, Chatelain E, Kaiser M, Wilkinson SR, McKenzie C, Ioset JR.

J Med Chem. 2012 Jun 14;55(11):5554-65. doi: 10.1021/jm300508n. Epub 2012 May 23.

17.

Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents.

Papadopoulou MV, Trunz BB, Bloomer WD, McKenzie C, Wilkinson SR, Prasittichai C, Brun R, Kaiser M, Torreele E.

J Med Chem. 2011 Dec 8;54(23):8214-23. doi: 10.1021/jm201215n. Epub 2011 Nov 4.

18.

Hypoxia-dependent retinal toxicity of NLCQ-1 (NSC 709257) in BALB/c mice. Comparison with tirapazamine.

Papadopoulou MV, Ji M, Bloomer WD.

Basic Clin Pharmacol Toxicol. 2011 Jun;108(6):396-9. doi: 10.1111/j.1742-7843.2010.00667.x. Epub 2011 Jan 26.

19.

The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.

Lunt SJ, Cawthorne C, Ali M, Telfer BA, Babur M, Smigova A, Julyan PJ, Price PM, Stratford IJ, Bloomer WD, Papadopoulou MV, Williams KJ.

Br J Cancer. 2010 Jul 13;103(2):201-8. doi: 10.1038/sj.bjc.6605753. Epub 2010 Jun 29.

20.

Investigational new drug-directed, 5-day repeat dose toxicity study of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1, NSC 709257) administered with or without Taxol in Sprague-Dawley rats.

Papadopoulou MV, Bloomer WD, Torti VR, Page JG.

Basic Clin Pharmacol Toxicol. 2010 Jun;106(6):497-504. doi: 10.1111/j.1742-7843.2009.00530.x. Epub 2010 Jan 14.

21.

Investigational new drug-directed toxicology and pharmacokinetic study of 4-[3-(2-nitro-1-imidazolyl)-propylamino]-7-chloroquinoline hydrochloride (NLCQ-1, NSC 709257) in Beagle dogs.

Papadopoulou MV, Bloomer WD, Torti VR, Page JG.

Basic Clin Pharmacol Toxicol. 2010 Jun;106(6):511-22. doi: 10.1111/j.1742-7843.2009.00532.x. Epub 2010 Jan 14.

22.

Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophore.

Papadopoulou MV, Bloomer WD.

Anticancer Drugs. 2009 Jul;20(6):493-502. doi: 10.1097/CAD.0b013e32832cad9b.

PMID:
19430289
23.

Gene therapy approaches to enhance bioreductive drug treatment.

Cowen RL, Garside EJ, Fitzpatrick B, Papadopoulou MV, Williams KJ.

Br J Radiol. 2008 Oct;81 Spec No 1:S45-56. doi: 10.1259/bjr/55070206. Review.

PMID:
18819998
25.

Interaction of strong DNA-intercalating bioreductive compounds with topoisomerases I and II.

Rosenzweig HS, Papadopoulou MV, Bloomer WD.

Oncol Res. 2005;15(4):219-31.

PMID:
17822282
26.

Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts.

Papadopoulou MV, Bloomer WD, Taylor AP, Hernandez M, Blumenthal RD, Hollingshead MG.

Radiat Res. 2007 Jul;168(1):65-71.

PMID:
17722994
28.

NLCQ-1 and NLCQ-2, two new agents with activity against dormant Mycobacterium tuberculosis.

Papadopoulou MV, Bloomer WD, McNeil MR.

Int J Antimicrob Agents. 2007 Jun;29(6):724-7. Epub 2007 Mar 26.

PMID:
17379483
29.
30.
31.

Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo.

Papadopoulou MV, Ji X, Bloomer WD.

J Exp Ther Oncol. 2006;5(4):261-72.

PMID:
17024967
32.
33.

NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts.

Papadopoulou MV, Bloomer WD, Hollingshead MG.

Anticancer Res. 2005 May-Jun;25(3B):1865-9.

35.

Synthesis of a novel nitroimidazole-spermidine derivative as a tumor-targeted hypoxia-selective cytotoxin.

Papadopoulou MV, Rosenzweig HS, Bloomer WD.

Bioorg Med Chem Lett. 2004 Mar 22;14(6):1519-22.

PMID:
15006394
36.

NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug.

Papadopoulou MV, Bloomer WD.

Clin Cancer Res. 2003 Nov 15;9(15):5714-20. Review.

37.

Reductive metabolism of the nitroimidazole-based hypoxia-selective cytotoxin NLCQ-1 (NSC 709257).

Papadopoulou MV, Ji M, Rao MK, Bloomer WD.

Oncol Res. 2003;14(1):21-9.

PMID:
14552588
38.
39.

Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.

Papadopoulou MV, Ji M, Ji X, Bloomer WD, Hollingshead MG.

Cancer Chemother Pharmacol. 2002 Dec;50(6):501-8. Epub 2002 Sep 26.

PMID:
12451478
40.

Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts.

Papadopoulou MV, Ji M, Bloomer WD, Hollingshead MG.

J Exp Ther Oncol. 2002 Sep-Oct;2(5):298-305.

PMID:
12416033
41.

Therapeutic advantage from combining 5-fluorouracil with the hypoxia-selective cytotoxin NLCQ-1 in vivo; comparison with tirapazamine.

Papadopoulou MV, Ji M, Ji X, Bloomer WD.

Cancer Chemother Pharmacol. 2002 Oct;50(4):291-8. Epub 2002 Jul 24.

PMID:
12357303
42.
45.
46.
47.

Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro.

Papadopoulou MV, Ji M, Khan SH, Bloomer WD.

Oncol Res. 1999;11(8):345-57.

PMID:
10803738
48.

NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo.

Papadopoulou MV, Ji M, Bloomer WD.

Int J Radiat Oncol Biol Phys. 1998 Nov 1;42(4):775-9.

PMID:
9845094

Supplemental Content

Loading ...
Support Center